The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

References

• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369(19):1783-96
   PubMed Web of Science ®Google Scholar
• Pazdur R. FDA Approval for Ponatinib Hydrochloride. National Cancer Institute. 2014. Available from: http://www.cancer.gov/cancertopics/druginfo/cancerconditions [Last accessed 2 January 2014]
   Google Scholar
• Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109(8):3189-97
   PubMed Web of Science ®Google Scholar
• Ribeiro RC, Abromowitch M, Raimondi SC, et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987;70(4):948-53
   PubMedGoogle Scholar
• Russo C, Carroll A, Kohler S, et al. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1991;77(5):1050-6
   PubMed Web of Science ®Google Scholar
• Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991;5(3):196-1991
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96(10):3343-56
   PubMed Web of Science ®Google Scholar
• Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010;115(2):206-14
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106(12):3760-7
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002;87(2):154-66
   PubMedGoogle Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396-407
   PubMed Web of Science ®Google Scholar
• Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008;143(4):503-10
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108(5):1469-77
   PubMed Web of Science ®Google Scholar
• de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109(4):1408-13
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010;95(1):87-95
   PubMedGoogle Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109(9):3676-8
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009;27(31):5175-81
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116(12):2070-7
   PubMed Web of Science ®Google Scholar
• Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 2014;89(3):282-7
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H, Cayuela JM, et al. Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02). ASH Annual Meeting Abstracts 2014. 124(21S):798
   Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100(6):1965-71
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Ravandi Kashani F, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). ASCO Annual Meeting Abstracts 2010. 28(15s):6506
   Google Scholar
• von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359(9305):487-91
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24(3):460-6
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011;118(25):6521-8
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113(5):985-94
   PubMedGoogle Scholar
• Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011;469(7330):362-7
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012;26(7):1475-81
   PubMed Web of Science ®Google Scholar
• Zhou T, Parillon L, Li F, et al. Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 2007;70(3):171-81
   PubMed Web of Science ®Google Scholar
• Buffa P, Romano C, Pandini A, et al. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. FASEB J 2014;28(3):1221-36
   PubMedGoogle Scholar
• Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53(12):4701-19
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16(5):401-12
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014;26(3):428-42
   PubMed Web of Science ®Google Scholar
• Cortes JE, Pinilla-Ibarz J, Le Coutre P, et al. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. ASH Annual Meeting Abstracts 2014. 124(21S):3135
   Google Scholar
• Jabbour E, Kantarjian HM, Thomas DA, et al. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting Abstracts 2014. 124(21S):2289
   Google Scholar
• Lipton JH, Chuah C, Guerci-Bresler A, et al. A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). ASH Annual Meeting Abstracts 2014. 124(21S):519
   Google Scholar
• Talpaz M, Cortes JE, Kantarjian HM, et al. Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. ASCO Annual Meeting Abstracts 2014. 32(15S):7018
   Google Scholar
• Larson RA, Kim DW, Issaragrilsil S, et al. Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. ASH Annual Meeting Abstracts 2014. 124(21S); abstract 4541
   Google Scholar
• Cortes JE, Saglio G, Baccarani M, et al. A Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). ASH Annual Meeting Abstracts 2014. 124(21S):152
   Google Scholar
• Dahlén T, Edgren G, Höglund M, et al. Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. ASH Annual Meeting Abstracts 2014. 124(21S):3134
   Google Scholar
• Khoury HJ, Cortes JE, Kim DW, et al. Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib. ASCO Annual Meeting Abstracts 2013. 31(15S):7048
   Google Scholar
• Valent P, Hadzijusufovic E, Schernthaner G, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2014; published online 18 December 2014; blood-2014-09-594432
   Google Scholar
• Hochhaus A, Pinilla-Ibarz J, Kim DW, et al. Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. ASCO Annual Meeting Abstracts 2014. 32(15S):7084
   Google Scholar
• Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013;121(7):1077-82
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007;109(10):2068-76
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010;28(22):3644-52
   PubMed Web of Science ®Google Scholar
• Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012;13(9):936-45
   PubMed Web of Science ®Google Scholar
• Rives S, Estella J, Gomez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011;154(5):600-11
   PubMedGoogle Scholar
• Jain P, Kantarjian HM, Jabbour E, et al. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). ASH Annual Meeting Abstracts 2014. 124(21S):4535
   Google Scholar